London, 19 April 2004 Doc. Ref: EMEA/CPMP/HMPWP/1513/04

PRESS RELEASE

Meeting of the Working Party on Herbal Medicinal Products

1-2 April 2004, EMEA London

The CPMP Working Party on Herbal Medicinal Products (HMPWP) met for the eighth time at the EMEA offices in London on 1-2 April 2004 under the chairmanship of Dr K. Keller.

The Chairman welcomed a new observer from the Accession Countries (Romania).

The following topics were addressed:

- The Working Party finalised the Position statement on **Chamomilla** containing herbal medicinal products (HMPWP/345/03)
- The HMPWP prepared a Draft 'Position paper on the use of herbal medicinal products containing **pulegone** and **menthofuran** (HMPWP/52/04)

This document is released for consultation until the end of August 2004.

• The HMPWP updated the "Compilation of general quality questions answered by the HMPWP' (EMEA/18123/00) to include recommendations on an appropriate declaration of active substances in finished herbal medicinal products, for standardised, quantified and other extracts.

In the margins of the meeting, the EMEA Director invited the Chair and Vice-Chairperson of the HMPWP to discuss a detailed action plan for the establishment of the future Committee for Herbal Medicinal Products (HMPC) at the EMEA. This action plan was subsequently presented to the HMPWP together with an overview of the major consequences related to the implementation of Directive 2004/24/EC regarding traditional herbal medicinal products at the level of the EMEA, HMPC and European Commission.

In preparation for the implementation of the above-mentioned Directive, the Working Party discussed a first draft template and procedure for the preparation of Community herbal monographs.

With the perspective of the new Committee for Herbal Medicinal Products, it has been agreed that the last HMPWP meeting would take place on 3 - 4 June 2004.

Dates for the future HMPC meetings in 2004 and 2005 have been proposed as follows:

- 23 24 September 2004
- 11 12 November 2004
- 27 28 January 2005
- 22 23 March 2005
- 31 May 1 June 2005
- 21 22 July 2005
- 19 20 September 2005
- 22 23 November 2005

Contact for further information:

Noël Wathion Head of Unit Post-Authorisation Evaluation of Medicines for Human Use Tel. (+44-20) 74 18 85 92)